2.4.0.8150 - Disclosure - SCHEDULE OF SALES BY PRODUCT TYPE (Details)truefalsefalse1false USDfalsefalse$P04_01_2013To06_30_2013http://www.sec.gov/CIK0001369868duration2013-04-01T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$P04_01_2012To06_30_2012http://www.sec.gov/CIK0001369868duration2012-04-01T00:00:002012-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$P01_01_2013To06_30_2013http://www.sec.gov/CIK0001369868duration2013-01-01T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$P01_01_2012To06_30_2012http://www.sec.gov/CIK0001369868duration2012-01-01T00:00:002012-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false 4us-gaap_Revenuesus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse5358052353580523USD$falsetruefalse2truefalsefalse5046633950466339USD$falsetruefalse3truefalsefalse107612255107612255USD$falsetruefalse4truefalsefalse9769380097693800USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 false2Sales2false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5false USDtruefalse$P04_01_2013To06_30_2013_HumanAlbuminMemberusgaapProductOrServiceAxishttp://www.sec.gov/CIK0001369868duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseHuman Albumin [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldicbpo_HumanAlbuminMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Human Albumin [Member]3false 4us-gaap_Revenuesus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse2276471122764711USD$falsefalsefalse2truefalsefalse1953941919539419USD$falsefalsefalse3truefalsefalse4326602243266022USD$falsefalsefalse4truefalsefalse4532970245329702USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 false2Sales4false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse9false USDtruefalse$P04_01_2013To06_30_2013_HumanImmunoglobulinForIntravenousInjectionMemberusgaapProductOrServiceAxishttp://www.sec.gov/CIK0001369868duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseHuman Immunoglobulin For Intravenous Injection [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldicbpo_HumanImmunoglobulinForIntravenousInjectionMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Human Immunoglobulin For Intravenous Injection [Member]5false 4us-gaap_Revenuesus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse2109715421097154USD$falsefalsefalse2truefalsefalse2123917421239174USD$falsefalsefalse3truefalsefalse4675902546759025USD$falsefalsefalse4truefalsefalse3650090036500900USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 false2Sales6false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse13false USDtruefalse$P04_01_2013To06_30_2013_OtherImmunoglobulinProductsMemberusgaapProductOrServiceAxishttp://www.sec.gov/CIK0001369868duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseOther Immunoglobulin Products [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldicbpo_OtherImmunoglobulinProductsMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Other Immunoglobulin Products [Member]7false 4us-gaap_Revenuesus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse54942615494261USD$falsefalsefalse2truefalsefalse69878226987822USD$falsefalsefalse3truefalsefalse1059398610593986USD$falsefalsefalse4truefalsefalse1077310110773101USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 false2Sales8false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse17false USDtruefalse$P04_01_2013To06_30_2013_PlacentaPolypeptideMemberusgaapProductOrServiceAxishttp://www.sec.gov/CIK0001369868duration2013-04-01T00:00:002013-06-30T00:00:00falsefalsePlacenta Polypeptide [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldicbpo_PlacentaPolypeptideMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Placenta Polypeptide [Member]9false 4us-gaap_Revenuesus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse30379913037991USD$falsefalsefalse2truefalsefalse25092022509202USD$falsefalsefalse3truefalsefalse52221545222154USD$falsefalsefalse4truefalsefalse46200114620011USD$falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 false2Sales10false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse21false USDtruefalse$P04_01_2013To06_30_2013_OtherCreditDerivativesMemberusgaapProductOrServiceAxishttp://www.sec.gov/CIK0001369868duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseOthers [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_OtherCreditDerivativesMemberus-gaap_ProductOrServiceAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0Others [Member]11false 4us-gaap_Revenuesus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse11864061186406USD$falsetruefalse2truefalsefalse190722190722USD$falsetruefalse3truefalsefalse17710681771068USD$falsetruefalse4truefalsefalse470086470086USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 false2SalesfalseSCHEDULE OF SALES BY PRODUCT TYPE (Details) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.chinabiologic.com/role/ScheduleOfSalesByProductTypeDetails411